Humanin (24-amino acid mitochondrial-derived peptide, MOTS-c sibling)

Humanin was identified in 2001 by Hashimoto and colleagues through a screen for factors that protect neurons from Alzheimer's-related apoptosis. The 24-amino-acid peptide turned out to be encoded within the 16S ribosomal RNA gene of mitochondrial DNA — making it the first identified "mitochondrial-derived peptide" (MDP) and the conceptual ancestor of what's now a growing family that includes MOTS-c, SHLPs (Small Humanin-Like Peptides), and several other recently-discovered MDPs.^[1]

The discovery was significant for two reasons. First, it demonstrated that mitochondria — long viewed as energy-producing organelles — also encode signaling peptides that act on whole-body biology. Second, the specific biology humanin engages (cytoprotection, anti-apoptotic signaling) is distinct from the metabolic signaling of MOTS-c and the structural function of SS-31, establishing the foundation for the multi-axis view of mitochondrial peptides that drives current research and community protocols.

Circulating humanin levels in human plasma decline with age, paralleling the decline of MOTS-c. Observational human data shows associations between higher humanin levels and better cognitive function, metabolic markers, and survival in elderly cohorts — though causation isn't established by observational data alone.

Humanin's mechanism centers on cytoprotection — protecting cells from various stress-induced death pathways. The molecular details:

• Receptor binding: Humanin binds a cell-surface receptor complex composed of FPRL1 (formyl peptide receptor-like 1), WSX-1, and gp130 — distinct from the receptor systems engaged by MOTS-c, SS-31, GLP-1 agonists, or other peptide therapeutics.
• Downstream signaling through STAT3: Receptor activation drives STAT3 phosphorylation and nuclear translocation, producing transcription of anti-apoptotic genes (Bcl-2 family upregulation) and reducing pro-apoptotic signaling (cytochrome c release, caspase activation).
• Anti-apoptotic effects in neurons: Particularly characterized in Alzheimer's-relevant contexts — humanin protects neurons from amyloid-β toxicity through the cytoprotective signaling cascade.
• Metabolic and insulin-sensitizing effects: Independent of the cytoprotective biology, humanin also acts on metabolic pathways — improving insulin sensitivity, glucose homeostasis, and reducing inflammatory markers in metabolic-stress contexts.
• Mitochondrial signaling: Although secreted from mitochondria and circulating systemically, humanin also has effects on mitochondrial function itself — supporting mitochondrial protein quality control and reducing oxidative damage.

Crucially for the "three-axis mitochondrial peptide" framing: humanin's cytoprotective biology doesn't substantially overlap with MOTS-c's metabolic-signaling role or SS-31's structural cardiolipin-binding mechanism. The three peptides target genuinely different aspects of cellular mitochondrial biology, which is why the combination framing has mechanistic coherence even where combination-specific evidence is absent.

The peer-reviewed literature on Humanin is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).

This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.

No clinical protocol exists. Research uses primarily characterize humanin's effects in cell culture and animal models. Within the small grey-market peptide community discussion of humanin, subcutaneous administration at experimental doses is the most-described route. Pharmacokinetic data for exogenous humanin in humans is essentially absent, making dose-response and timing recommendations speculative.

For users interested in the broader mitochondrial-peptide approach, MOTS-c and SS-31 have substantially more characterized pharmacokinetics and clinical-trial dosing patterns to anchor experimental use. Humanin is genuinely earlier in this development arc.

Humanin is genuinely interesting biology and the conceptual third axis of the mitochondrial-peptide story — sitting alongside MOTS-c (metabolic signaling) and SS-31 (structural mitochondrial protection) as the cytoprotective and anti-apoptotic entry. The mechanism is well-characterized, the preclinical evidence is substantial, and the observational human data supports the underlying biological relevance.

It is also, currently, an "interesting research direction" rather than a clinical intervention. The translation gap from observational and preclinical evidence to validated human use is wider for humanin than for MOTS-c or SS-31, both of which have meaningful clinical-trial activity humanin lacks. For users committed to mitochondrial-peptide exploration and willing to bet on mechanism rather than outcome data, humanin completes the three-axis framing alongside MOTS-c and SS-31. For users wanting evidence-based mitochondrial intervention, the order of credibility currently runs SS-31 → MOTS-c → humanin, with the gap between MOTS-c and humanin being meaningful. See our MOTS-c + SS-31 together or separate article for the broader framework — humanin extends that decision matrix without resolving it.